中药在儿童肿瘤学中的作用:生存与毒性影响的Meta分析
该系统评价与Meta分析纳入49项RCT,评估中药作为儿童肿瘤常规治疗辅助手段的疗效。结果显示中药可提高完全缓解率(OR: 1.82; 95% CI: [1.44-2.29])和部分缓解率(OR: 2.92; 95% CI: [2.23-3.83]),改善免疫指标,并降低感染、恶心呕吐及心电图异常发生率。结论认为中药有潜力作为辅助治疗,但需更多大规模多中心试验确立标准化方案。
要点
- 中药辅助治疗可提高儿童肿瘤完全缓解率(OR: 1.82; 95% CI: [1.44-2.29])。
- 中药可提升CD4+计数(MD: 7.30; 95% CI: [5.70-8.91])及CD4+/CD8+比值(MD: 0.27; 95% CI: [0.18-0.35])。
- 中药降低感染率(OR: 0.37; 95% CI: [0.26-0.52])和恶心呕吐(OR: 0.43; 95% CI: [0.30-0.62])。
核心结论
- 中药作为儿童肿瘤常规治疗的辅助手段,可提高缓解率、改善免疫功能并减少治疗相关毒性。
- 目前证据仍限于Meta分析层面,需大规模多中心试验确立标准化整合方案。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA 2020指南,方案注册于PROSPERO(CRD42023422125)。
- 检索中英文数据库纳入儿童肿瘤患者接受中药联合常规治疗的随机对照试验(RCT),最终纳入49项RCT,涉及29种中药处方和136种成分。
主要发现
- 完全缓解率OR: 1.82(95% CI: [1.44-2.29]),部分缓解率OR: 2.92(95% CI: [2.23-3.83])。
- CD4+计数MD: 7.30(95% CI: [5.70-8.91]),CD4+/CD8+比值MD: 0.27(95% CI: [0.18-0.35])。
- 血小板计数MD: 17.02(95% CI: [7.60-26.44]),中性粒细胞计数MD: 0.65(95% CI: [0.17-1.13])。
- 感染率OR: 0.37(95% CI: [0.26-0.52]),恶心/呕吐OR: 0.43(95% CI: [0.30-0.62]),心电图异常OR: 0.39(95% CI: [0.16-0.93])。
临床怎么用
- 在儿童肿瘤常规治疗基础上,可考虑联合中药以改善缓解率、免疫功能和减少感染及胃肠道毒性。
- 具体中药处方需基于纳入研究的29种处方和136种成分进一步个体化评估,目前尚无统一标准方案。
局限性
- 需进一步大规模、多中心试验以确立中药整合入儿童肿瘤治疗的标准化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric oncology treatment often involves aggressive therapies causing significant side effects, including immune suppression, gastrointestinal disturbances, and hematological toxicities. Although Chinese Herbal Medicine (CHM) has shown promise in mitigating adverse effects and enhancing overall treatment outcomes, there is a need for comprehensive evidence assessments conducted with scientific rigor to validate its role within evidence-based medicine. OBJECTIVE: This systematic review and meta-analysis evaluates the efficacy of CHM as an adjunct to conventional cancer therapies in pediatric oncology, focusing on reducing treatment-related toxicities, improving immune function and remission rates. METHODS: A comprehensive search of English and Chinese databases was conducted to identify randomized controlled trials (RCTs) involving pediatric oncology patients treated with CHM alongside conventional therapies. After study selection, data on clinical outcomes were extracted such as remission rates, immune parameters, and incidence of adverse effects. Odds ratios (OR) and mean differences (MD) were pooled with subgroup analysis. This review was conducted following PRISMA 2020 guidelines. The pre-study protocol was registered with PROSPERO (CRD42023422125). RESULTS: A total of 49 RCTs involving 29 different herbal prescriptions and 136 substances were meta-analyzed. CHM significantly improved complete remission rates (OR: 1.82; 95% CI: [1.44-2.29]) and partial remission rates (OR: 2.92; 95% CI: [2.23-3.83]). CHM also enhanced immune parameters, including increases in CD4+ counts (MD: 7.30; 95% CI: [5.70-8.91]) and CD4+/CD8+ ratio (MD: 0.27; 95% CI: [0.18-0.35]). Hematological stability was supported through improved platelet (MD: 17.02; 95% CI: [7.60-26.44]) and neutrophil counts (MD: 0.65; 95% CI: [0.17-1.13]). CHM significantly reduced infection rates (OR: 0.37; 95% CI: [0.26-0.52]), nausea/vomiting (OR: 0.43; 95% CI: [0.30-0.62]), and ECG abnormalities (OR: 0.39; 95% CI: [0.16-0.93]). These findings suggest CHM contributes to both enhanced efficacy and reduced toxicity during pediatric cancer treatment. CONCLUSION: CHM shows promise as a complementary therapy in pediatric oncology, particularly in reducing the toxicities of conventional cancer treatments and supporting immune function. However, further large-scale, multicenter trials are needed to establish standardized protocols for its integration of CHM into pediatric cancer care.
引用
- Li X, Cai G, Hernádfői MV, et al. Chinese herbal medicine in pediatric oncology: Effects on survival and toxicity - a meta-analysis. Phytomedicine. 2025. PMID: 41447839. doi:10.1016/j.phymed.2025.157723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。